Results 21 to 30 of about 545,624 (314)

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Nature, 2021
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1–3.
J. Robichaux, X. Le, R. Vijayan, J. K. Hicks, S. Heeke, Y. Elamin, Heather Y. Lin, H. Udagawa, F. Skoulidis, H. Tran, S. Varghese, Junqin He, Fahao Zhang, M. Nilsson, Lemei Hu, A. Poteete, W. Rinsurongkawong, Xiaoshan Zhang, C. Ren, Xiaoke Liu, L. Hong, Jianjun Zhang, L. Diao, R. Madison, A. Schrock, J. Saam, V. Raymond, B. Fang, Jing Wang, M. Ha, J. Cross, J. Gray, J. Heymach   +32 more
semanticscholar   +1 more source

An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1

Cancer Cell, 2010
SUMMARY The Cancer Genome Atlas Network recently catalogued recurrent genomic abnormalities in glioblastoma (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical and Mesenchymal subtypes and ...
R. Verhaak, K. Hoadley, E. Purdom, V. Wang, Y. Qi, M. Wilkerson, C. Miller, L. Ding, Todd Golub, J. Mesirov, Gabriele Alexe, M. Lawrence, Michael J. T. O’Kelly, P. Tamayo, B. Weir, S. Gabriel, W. Winckler, Supriya Gupta, L. Jakkula, H. Feiler, J. Hodgson, C. James, J. Sarkaria, C. Brennan, A. Kahn, P. Spellman, R. Wilson, T. Speed, J. Gray, M. Meyerson, G. Getz, C. Perou, D. Hayes   +32 more
semanticscholar   +1 more source

Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation [PDF]

Pharmaceutical Sciences
Background: The therapeutic potential of epidermal growth factor receptor (EGFR) targeting in colorectal cancer (CRC) is hindered by the presence of KRAS codon 12 activating mutations, prevalent in approximately 25% of advanced CRC cases.
Maedeh Yousefi, Hamed Farzi-Khajeh, Mostafa Akbarzadeh-Khiavi, Azam Safary, Khosro Adibkia   +4 more
doaj   +1 more source

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

Cancers, 2021
Simple Summary Growth factors are hormone-like molecules able to promote division and migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor growth and metastasis. Here we review the epidermal growth factor (EGF), which
M. L. Uribe, Ilaria Marrocco, Y. Yarden
semanticscholar   +1 more source

EGFR‐AS1 Promotes Bladder Cancer Progression by Upregulating EGFR [PDF]

BioMed Research International, 2020
Long noncoding RNAs play an essential role in bladder cancer progression. The role of long noncoding RNA EGFR‐AS1 in bladder cancer needs further study. We used clinical specimens to analyze the relationship between EGFR‐AS1 and bladder cancer patients’ characteristics.
Anbang Wang, Aimin Jiang, Xinxin Gan, Zheng Wang, Jinming Huang, Kai Dong, Bing Liu, Linhui Wang, Ming Chen   +8 more
openaire   +2 more sources

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Science Translational Medicine, 2011
Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors. The Shifting Sands of Lung Cancer Lung cancer is the leading cause of death globally and has proven very difficult to treat.
L. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, Alexa B. Turke, P. Fidias, K. Bergethon, A. Shaw, S. Gettinger, A. Cosper, S. Akhavanfard, R. Heist, J. Temel, J. Christensen, J. Wain, T. Lynch, Kathy Vernovsky, E. Mark, M. Lanuti, A. Iafrate, M. Mino‐Kenudson, J. Engelman   +21 more
semanticscholar   +1 more source

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth [PDF]

Signal Transduction and Targeted Therapy, 2020
AbstractEpidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy. EGFR tyrosine kinase inhibitors (TKIs) have been canonically used in NSCLC treatment.
Nan Yao, Chen-Ran Wang, Ming-Qun Liu, Ying-Jie Li, Wei-Min Chen, Zheng-Qiu Li, Qi Qi, Jin-Jian Lu, Chun-Lin Fan, Min-Feng Chen, Ming Qi, Xiao-Bo Li, Jian Hong, Dong-Mei Zhang, Wen-Cai Ye   +14 more
openaire   +2 more sources

Blockade of Radiation-induced EGFR Nuclear Transport Enhances Radiosensitivity of Human Cervical Cancer

Zhongliu Fangzhi Yanjiu, 2020
Objective To investigate whether the inhibition of EGFR nuclear transport could reduce the radioresistance of human cervical cancer cells. Methods Human cervical cancer CaSki and HeLa cells were exposed to radiation treated with or without Thr654 ...
LI Lu, HUANG Jianming, FENG Mei, QI Yunxiang, MA Shiqi, TAN Mingyu, LANG Jinyi   +6 more
doaj   +1 more source

eGFR [PDF]

Clinical Journal of the American Society of Nephrology, 2009
GFR is the accepted metric for evaluating renal function but measuring it directly (mGFR) can be cumbersome, time-consuming, and costly. The constant infusion method using inulin as the filtration marker, introduced in 1934 by Richards and Smith (1), has undergone many revisions that have now made mGFR easier to perform, although not widely available ...
Richard J. Glassock, Christopher G. Winearls   +1 more
openaire   +1 more source

Canine parvovirus induces G1/S cell cycle arrest that involves EGFR Tyr1086 phosphorylation

Virulence, 2020
Canine parvovirus (CPV) has been used in cancer control as a drug delivery vehicle or anti-tumor reagent due to its multiple natural advantages. However, potential host cell cycle arrest induced by virus infection may impose a big challenge to CPV ...
Xiaofeng Dai, Xuanhao Zhang, Yujie Miao, Peiyu Han, Jianying Zhang   +4 more
doaj   +1 more source